DFO
RYTM icon

Duquesne Family Office’s Rhythm Pharmaceuticals RYTM Stock Holding History

Duquesne Family Office’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Buy
+203,618
New +$18.4M 0.43% 48

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Duquesne Family Office's RYTM Position: Q2 2026 in Review

Duquesne Family Office opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 203,618 shares worth $22.6M. The stake represents 0.43% of the portfolio and ranks #48 among its holdings.

303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Duquesne Family Office held 203,618 shares of Rhythm Pharmaceuticals worth $22.6M as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Duquesne Family Office position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.43% of Duquesne Family Office's portfolio in Q2 2026, its #48 holding.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.